On June 29, 2020, Burning Rock Biotech Limited (NASDAQ: BNR) announced a strategic partnership with CStone Pharmaceuticals (HKEX: 2616) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s...
2020
2024
2023
2022
2021
2020
Burning Rock deepens cooperation with Illumina to promote development and standardization of NGS-based cancer therapy selection [in China]
SHANGHAI, China, May 11, 2020-- Burning Rock and Illumina (NASDAQ: ILMN), a global leader in gene sequencing and array-based technologies, jointly announced today that they are joining forces to promote the development and standardization of NGS-based cancer therapy...
Burning Rock initiates the first prospective, multi-center pan-cancer early detection study in China
SHANGHAI, China, May 07, 2020 (GLOBE NEWSWIRE) -- Burning Rock today announces the initiation of its 14,000 patient PREDICT (Pan-CanceR Early DetectIon ProjeCT) study to further develop and validate its pan-cancer early detection technology. PREDICT will be the first...